Moneycontrol PRO
HomeNewsBusinessStocksAngel Broking neutral on Dr Reddys Laboratories

Angel Broking neutral on Dr Reddys Laboratories

Angel Broking has maintained a neutral rating on Dr Reddys Laboratories (DRL) in its February 21, 2013 research report. The research firm expects net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E.

February 23, 2013 / 17:43 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Angel Broking has maintained a neutral rating on Dr Reddys Laboratories (DRL) in its February 21, 2013 research report. The research firm expects net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E.


    "DRL reported more or less just-in 3QFY2013 top-line and bottom-line performance. The company's net sales increased by 3.5% yoy (23% adjusted for the base effect). The growth came in on back of 24% yoy (adjusted) in the US and Emerging Markets. On the EBIT margins came in at 15.0% V/s expected 15.8%. Consequently the net profit came in at Rs 363cr, a dip of 29.1%, mostly in line with expectations of Rs 339cr.


    DRL reported net sales of Rs 2,865cr for 3QFY2013, registering 23.0% yoy growth, which was a tad lower than our estimate of Rs 2,700cr. The U.S. and Emerging markets grew by 24% yoy (adjusted) were the key growth drivers for the company. The domestic market reported a strong growth of 12.0% yoy. On the positive side the PSAI segment posted a robust growth of 28.0% yoy during the quarter. The company's EBIT margin came in at 15.0% V/s expected 15.8% and contracting by 11.7%, leading to a dip of 29.1% to Rs 363cr during the quarter.


    DRL has reinforced its earlier revenue guidance of US$2.7bn by FY2013E with RoCE of 25%. We expect net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E. We maintain our neutral on the stock," says Angel Broking research report.


    Shares held by Mutual Funds/UTI


    Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

    To read the full report click on the attachment

    first published: Feb 23, 2013 05:43 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347